PAI-1 Overexpression in Valvular Interstitial Cells Contributes to Hypofibrinolysis in Aortic Stenosis.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
16 05 2023
Historique:
received: 23 03 2023
revised: 11 05 2023
accepted: 15 05 2023
medline: 7 7 2023
pubmed: 6 7 2023
entrez: 6 7 2023
Statut: epublish

Résumé

Aortic stenosis (AS) is associated with hypofibrinolysis, but its mechanism is poorly understood. We investigated whether LDL cholesterol affects plasminogen activator inhibitor 1 (PAI-1) expression, which may contribute to hypofibrinolysis in AS. Stenotic valves were obtained from 75 severe AS patients during valve replacement to assess lipids accumulation, together with PAI-1 and nuclear factor-κB (NF-κB) expression. Five control valves from autopsy healthy individuals served as controls. The expression of PAI-1 in valve interstitial cells (VICs) after LDL stimulation was assessed at protein and mRNA levels. PAI-1 activity inhibitor (TM5275) and NF-κB inhibitor (BAY 11-7082) were used to suppress PAI-1 activity or NF-κB pathway. Clot lysis time (CLT) was performed to assess fibrinolytic capacity in VICs cultures. Solely AS valves showed PAI-1 expression, the amount of which was correlated with lipid accumulation and AS severity and co-expressed with NF-κB. In vitro VICs showed abundant PAI-1 expression. LDL stimulation increased PAI-1 levels in VICs supernatants and prolonged CLT. PAI-1 activity inhibition shortened CLT, while NF-κB inhibition decreased PAI-1 and SERPINE1 expression in VICs, its level in supernatants and shortened CLT. In severe AS, valvular PAI-1 overexpression driven by lipids accumulation contributes to hypofibrinolysis and AS severity.

Identifiants

pubmed: 37408236
pii: cells12101402
doi: 10.3390/cells12101402
pmc: PMC10216522
pii:
doi:

Substances chimiques

Lipids 0
NF-kappa B 0
Plasminogen Activator Inhibitor 1 0
SERPINE1 protein, human 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Thromb Haemost. 2011 Feb;105(2):254-60
pubmed: 21057695
J Thromb Haemost. 2013 Apr;11(4):733-40
pubmed: 23289423
Thromb Haemost. 2015 Aug;114(2):217-27
pubmed: 25809537
Cardiovasc Diabetol. 2020 Jun 17;19(1):92
pubmed: 32552684
Cardiovasc Pathol. 2005 Mar-Apr;14(2):80-7
pubmed: 15780799
Cardiovasc Ther. 2010 Oct;28(5):e72-91
pubmed: 20626406
Atherosclerosis. 2014 Mar;233(1):104-12
pubmed: 24529130
J Clin Med. 2020 Jun 25;9(6):
pubmed: 32630544
Am J Pathol. 2007 Nov;171(5):1407-18
pubmed: 17823281
PLoS One. 2016 Feb 11;11(2):e0148747
pubmed: 26866684
Diabetologia. 2021 Nov;64(11):2562-2574
pubmed: 34494136
J Cell Biochem. 2015 Nov;116(11):2427-34
pubmed: 25974396
Clin Cancer Res. 1999 Aug;5(8):2094-102
pubmed: 10473092
Arterioscler Thromb Vasc Biol. 2020 Jun;40(6):1479-1490
pubmed: 32268785
Invest Ophthalmol Vis Sci. 2016 Sep 1;57(11):4704-12
pubmed: 27607416
J Pathol. 2010 May;221(1):37-48
pubmed: 20186923
J Am Coll Cardiol. 2015 Aug 4;66(5):561-77
pubmed: 26227196
Atherosclerosis. 2022 Mar;344:49-56
pubmed: 35134656
Am J Physiol Cell Physiol. 2008 Jan;294(1):C29-35
pubmed: 17942642
Thromb Res. 2013 Jul;132(1):100-5
pubmed: 23611258
Int J Mol Sci. 2020 Jul 21;21(14):
pubmed: 32708302
EuroIntervention. 2022 Feb 04;17(14):e1126-e1196
pubmed: 34931612
J Thromb Haemost. 2003 Nov;1(11):2389-96
pubmed: 14629474
Int J Mol Sci. 2020 Sep 25;21(19):
pubmed: 32993026
Thromb J. 2018 Jun 05;16:12
pubmed: 29991926
J Thromb Haemost. 2018 May;16(5):1007-1012
pubmed: 29658191
Arterioscler Thromb Vasc Biol. 2020 May;40(5):1370-1382
pubmed: 32188274
Vascul Pharmacol. 2020 Jul;130:106679
pubmed: 32387621
J Am Coll Cardiol. 1993 Apr;21(5):1220-5
pubmed: 8459080

Auteurs

Magdalena Kopytek (M)

Thromboembolic Disorders Department, Institute of Cardiology, Jagiellonian University Medical College, 80 Pradnicka St., 31-202 Krakow, Poland.
Krakow Centre for Medical Research and Technologies, John Paul II Hospital, 80 Pradnicka St., 31-202 Krakow, Poland.

Michał Ząbczyk (M)

Thromboembolic Disorders Department, Institute of Cardiology, Jagiellonian University Medical College, 80 Pradnicka St., 31-202 Krakow, Poland.
Krakow Centre for Medical Research and Technologies, John Paul II Hospital, 80 Pradnicka St., 31-202 Krakow, Poland.

Piotr Mazur (P)

Department of Cardiovascular Surgery, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.
Department of Cardiovascular Surgery and Transplantology, Institute of Cardiology, Jagiellonian University Medical College, 80 Pradnicka St., 31-202 Krakow, Poland.

Anetta Undas (A)

Thromboembolic Disorders Department, Institute of Cardiology, Jagiellonian University Medical College, 80 Pradnicka St., 31-202 Krakow, Poland.
Krakow Centre for Medical Research and Technologies, John Paul II Hospital, 80 Pradnicka St., 31-202 Krakow, Poland.

Joanna Natorska (J)

Thromboembolic Disorders Department, Institute of Cardiology, Jagiellonian University Medical College, 80 Pradnicka St., 31-202 Krakow, Poland.
Krakow Centre for Medical Research and Technologies, John Paul II Hospital, 80 Pradnicka St., 31-202 Krakow, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH